Cargando…
SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
BACKGROUND: Studies evaluating neutralizing antibody (NAb) after BNT162b2 vaccine are scarce. We therefore compared NAb using the plaque reduction neutralization test (PRNT) in vaccinated subjects, with those from five chemiluminescent (CLIA) assays, two targeting ACE and S-RBD interaction. METHODS:...
Autores principales: | Padoan, Andrea, Cosma, Chiara, Bonfante, Francesco, Rocca, Foscarina della, Barbaro, Francesco, Santarossa, Claudia, Dall'Olmo, Luigi, Pagliari, Matteo, Bortolami, Alessio, Cattelan, Annamaria, Cianci, Vito, Basso, Daniela, Plebani, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553360/ https://www.ncbi.nlm.nih.gov/pubmed/34755646 http://dx.doi.org/10.1016/j.cca.2021.10.028 |
Ejemplares similares
-
Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
por: Padoan, Andrea, et al.
Publicado: (2021) -
Érythème pigmenté fixe après vaccin anti-COVID-19 Comirnaty® de Pfizer/BioNTech
por: Lellig, Elodie, et al.
Publicado: (2021) -
Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021) -
Subacute monomelic radiculoplexus neuropathy following Comirnaty© (Pfizer-BioNTech COVID-19) vaccination: A case report
por: Coly, M., et al.
Publicado: (2023) -
A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)